$55m For Akebia As Otsuka Confirms Vadadustat Exit
Executive Summary
Japanese firm extricates itself from international deals for oral anemia drug, leaving Akebia potentially needing to find a new partner to progress development and commercialization.
You may also be interested in...
Deal Watch: Sanofi Offloads Established Products, Lilly Testing 3D-Printed Drugs
Specialty pharma Neuraxpharm is taking on 38 mature brands from Sanofi, in CNS, pain and vascular diseases. Lilly is working with Triastek on 3D printing technology for targeted release of drugs in specific regions of the gastrointestinal tract.
Will 2022 Be US FDA’s Year Of ‘No’? Approval Rate For Novel Agents Plunged In First Half
With 19 novel approvals and 14 complete response letters in the first half of 2022, the year is shaping up to be a turnabout from the big approval counts and rare CRLs of the recent approvals boom years.
GSK Can Seize Chance In Anemia After Rivals Rejected But FDA Caution Will Remain
GSK’s drug is the first in the class to show non-inferiority to standard therapy in safety, but the data still contains areas of doubt.